{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:08:24Z","timestamp":1789787304153,"version":"4.0.1"},"reference-count":57,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"KWF Dutch Cancer Society","award":["11289"],"award-info":[{"award-number":["11289"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Radiolabelled fibroblast activation protein inhibitor (FAPI) tracers have the potential to overcome the limitations of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) and improve the diagnosis and staging of hepato-pancreato-biliary (HPB) cancers. This study aims to compare the diagnostic performance of radiolabelled FAPI versus [18F]FDG PET imaging in HPB cancers. A systematic search of PubMed, Embase, Web of Science and Cochrane Library was performed to identify eligible studies on the diagnostic performance of FAPI PET for primary HPB tumours (hepatocellular carcinoma (HCC), pancreatic cancer (PC) and biliary tract cancer (BTC)) and for liver metastases of gastrointestinal origin. The diagnostic performance was defined as a combination of detection rate and semi-quantitative tracer uptake. A random-effects model was used to calculate the risk differences. In total, 28 studies were included. Histopathology was the reference standard for the primary tumour in 26 studies (93%). The detection rate of radiolabelled FAPI in comparison to [18F]FDG was significantly higher in HCC (0.33, 95% CI: 0.20\u20130.47 and 0.34, 95% CI: 0.23\u20130.45) and BTC (0.27, 95% CI: 0.11\u20130.43 and 0.28, 95% CI: 0.08\u20130.48), in the patient- and lesion-based analyses, respectively. In PC, no differences were observed. Radiolabelled FAPI outperformed [18F]FDG in the lesion-based detection of lymph node, liver and extra-hepatic metastases. In all HPB cancers, the mean SUVmax was significantly higher with radiolabelled FAPI compared to [18F]FDG. Molecular imaging with FAPI PET seems to have several benefits over [18F]FDG PET in HPB cancer diagnostics, with an overall higher tracer uptake, and higher detection rates in HCC and BTC.<\/jats:p>","DOI":"10.3390\/ijms26051978","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:13:18Z","timestamp":1740463998000},"page":"1978","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diagnostic Performance of Radiolabelled FAPI Versus [18F]FDG PET Imaging in Hepato-Pancreato-Biliary Oncology: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5302-1392","authenticated-orcid":false,"given":"Rutger B.","family":"Henrar","sequence":"first","affiliation":[{"name":"Department of Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, Van der Boechorststraat 6B, 1081 BT Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7888-924X","authenticated-orcid":false,"given":"Floris A.","family":"Vuijk","sequence":"additional","affiliation":[{"name":"Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Burchell","sequence":"additional","affiliation":[{"name":"Medical Library, Vrije Universiteit Amsterdam, de Boelelaan 1118, 1081 HV Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"van Dieren","sequence":"additional","affiliation":[{"name":"Department of Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, Van der Boechorststraat 6B, 1081 BT Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-2743","authenticated-orcid":false,"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Kazemier","sequence":"additional","affiliation":[{"name":"Department of Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, Van der Boechorststraat 6B, 1081 BT Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[{"name":"Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, Van der Boechorststraat 6B, 1081 BT Amsterdam, The Netherlands"},{"name":"Department of Medical Imaging, Radboud University Medical Center, Geert Grootplein Zuid 10, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger-Jan","family":"Swijnenburg","sequence":"additional","affiliation":[{"name":"Department of Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"},{"name":"Cancer Center Amsterdam, Imaging and Biomarkers, Van der Boechorststraat 6B, 1081 BT Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101760","DOI":"10.1016\/j.canep.2020.101760","article-title":"Epidemiology of liver metastases","volume":"67","author":"Horn","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000453009","article-title":"Imaging of Cholangiocarcinoma","volume":"32","author":"Olthof","year":"2016","journal-title":"Visc. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1259\/bjr\/88405305","article-title":"Radiological staging in patients with hilar cholangiocarcinoma: A systematic review and meta-analysis","volume":"85","author":"Ruys","year":"2012","journal-title":"Br. J. Radiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1007\/s00330-016-4632-8","article-title":"CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma","volume":"27","author":"Wagner","year":"2017","journal-title":"Eur. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22070","article-title":"PET-PANC: Multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer","volume":"22","author":"Ghaneh","year":"2018","journal-title":"Health Technol. Assess."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cpet.2022.03.007","article-title":"18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies","volume":"17","author":"Gnanasegaran","year":"2022","journal-title":"PET Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","article-title":"18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis","volume":"71","author":"Lamarca","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.ejrad.2011.08.004","article-title":"18F-FDG PET or PET\/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis","volume":"81","author":"Lin","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cpet.2023.02.007","article-title":"Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation","volume":"18","author":"Mori","year":"2023","journal-title":"PET Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2021.03.006","article-title":"Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment","volume":"82","author":"Boyd","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_17","first-page":"1669","article-title":"Clinical relevance of biomarkers in cholangiocarcinoma: Critical revision and future directions","volume":"71","author":"Macias","year":"2022","journal-title":"Gut"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-019-0782-x","article-title":"Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma","volume":"12","author":"Yin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liu, F., Qi, L., Liu, B., Liu, J., Zhang, H., Che, D., Cao, J., Shen, J., Geng, J., and Bi, Y. (2015). Fibroblast activation protein overexpression and clinical implications in solid tumors: A meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116683"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3748\/wjg.v18.i8.840","article-title":"Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance","volume":"18","author":"Shi","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Waki, Y., Morine, Y., Noma, T., Takasu, C., Teraoku, H., Yamada, S., Saito, Y., Ikemoto, T., and Shimada, M. (2023). Association between high expression of intratumoral fibroblast activation protein and survival in patients with intrahepatic cholangiocarcinoma. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-03012-x"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wan, X., Wang, W., Liu, J., and Tong, T. (2014). Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-135"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/RLU.0000000000004073","article-title":"Tumor Imaging With 68Ga-DOTA-FAPI-04 PET\/CT: Comparison With 18F-FDG PET\/CT in 22 Different Cancer Types","volume":"47","author":"Cermik","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-021-05488-9","article-title":"FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies","volume":"49","author":"Dendl","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","article-title":"Imaging fibroblast activation protein in liver cancer: A single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT","volume":"48","author":"Guo","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2967\/jnumed.122.264689","article-title":"Fibroblast activation protein positron emission tomography and histopathology in a single-center database of 324 patients and 21 tumor entities","volume":"64","author":"Hirmas","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.2020203275","article-title":"Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers","volume":"298","author":"Pang","year":"2021","journal-title":"Radiology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","article-title":"Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer","volume":"49","author":"Pang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s12149-021-01673-w","article-title":"Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET\/CT","volume":"35","author":"Zheng","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","article-title":"The Role of 68Ga-FAPI PET\/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience","volume":"61","author":"Koerber","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of 68Ga-FAPI PET\/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas","volume":"62","author":"Rohrich","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","article-title":"Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings","volume":"48","author":"Chen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11307-022-01729-x","article-title":"Comparison of 68Ga-FAPI PET\/CT and 18FDG PET\/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement","volume":"24","author":"Elboga","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MNM.0000000000001489","article-title":"Comparison of 18F-FDG PET\/CT and 68Ga-FAPI-04 PET\/CT in the staging and restaging of gastric adenocarcinoma","volume":"43","author":"Gundogan","year":"2022","journal-title":"Nucl. Med. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1007\/s00259-022-05839-0","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 PET\/CT and [18F]FDG PET\/CT in colorectal cancer","volume":"49","author":"Komek","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00259-021-05522-w","article-title":"The potential utility of [68Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG","volume":"49","author":"Lan","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1148\/radiol.213118","article-title":"Prospective Comparison of 68Ga-FAPI versus 18F-FDG PET\/CT for Tumor Staging in Biliary Tract Cancers","volume":"304","author":"Lan","year":"2022","journal-title":"Radiology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00330-022-09251-y","article-title":"Usefulness of [68Ga]FAPI-04 and [18F]FDG PET\/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: A comparative study","volume":"33","author":"Li","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lin, X., Li, Y., Wang, S., Zhang, Y., Chen, X., Wei, M., Zhu, H., Wu, A., Yang, Z., and Wang, X. (2022). Diagnostic value of [68Ga]Ga-FAPI-04 in patients with colorectal cancer in comparison with [18F]F-FDG PET\/CT. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.978506"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.122.264544","article-title":"PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"109867","DOI":"10.1016\/j.ejrad.2021.109867","article-title":"Comparison of 68Ga-DOTA-FAPI and 18FDG PET\/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer","volume":"142","author":"Sahin","year":"2021","journal-title":"Eur. J. Radiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","article-title":"Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: A prospective pilot study","volume":"48","author":"Shi","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","article-title":"Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET\/CT: A pilot study in patients with suspected hepatic nodules","volume":"48","author":"Shi","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s11307-022-01732-2","article-title":"Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET\/CT and [18F]F-FDG PET\/CT in Patients with Liver Malignancies","volume":"24","author":"Siripongsatian","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhu, W., Ren, S., Kong, Y., Huang, Q., Zhao, J., Guan, Y., Jia, H., Chen, J., and Lu, L. (2021). 68Ga-FAPI-04 Versus 18F-FDG PET\/CT in the Detection of Hepatocellular Carcinoma. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.693640"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00259-022-05955-x","article-title":"[18F]FAPI-42 PET\/CT versus [18F]FDG PET\/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors","volume":"50","author":"Wu","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","article-title":"[18F]FAPI PET\/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity","volume":"50","author":"Zhang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s00259-022-05729-5","article-title":"Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET\/MR and 18F-FDG PET\/CT in patients with pancreatic cancer","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/RLU.0000000000004438","article-title":"Comparison of the Detection Performance Between FAP and FDG PET\/CT in Various Cancers: A Systemic Review and Meta-analysis","volume":"48","author":"Chang","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s00259-022-06021-2","article-title":"[68Ga]Ga-FAPI PET for the evaluation of digestive system tumors: Systematic review and meta-analysis","volume":"50","author":"Huang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Veldhuijzen van Zanten, S.E.M., Pieterman, K.J., Wijnhoven, B.P.L., Pruis, I.J., Groot Koerkamp, B., van Driel, L., Verburg, F.A., and Thomeer, M.G.J. (2022). FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances. Diagnostics, 12.","DOI":"10.3390\/diagnostics12081958"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41416-022-01748-z","article-title":"Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging","volume":"127","author":"Strating","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/1978\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:59Z","timestamp":1760028119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/1978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26051978"],"URL":"https:\/\/doi.org\/10.3390\/ijms26051978","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}